Earnings summaries and quarterly performance for Zoetis.
Executive leadership at Zoetis.
Kristin Peck
Detailed
Chief Executive Officer
CEO
JB
Jamie Brannan
Executive Vice President and Chief Commercial Officer
RP
Robert Polzer
Executive Vice President and President, Research and Development
RL
Roxanne Lagano
Executive Vice President, General Counsel and Corporate Secretary
WJ
Wetteny Joseph
Executive Vice President and Chief Financial Officer
Board of directors at Zoetis.
AL
Antoinette Leatherberry
Detailed
Director
FD
Frank D'Amelio
Detailed
Director
GH
Gavin Hattersley
Detailed
Director
GN
Gregory Norden
Detailed
Director
LP
Louise Parent
Detailed
Director
MS
Mark Stetter
Detailed
Director
MM
Michael McCallister
Detailed
Chair of the Board
PB
Paul Bisaro
Detailed
Director
SK
Sanjay Khosla
Detailed
Director
ST
Stephanie Tilenius
Detailed
Director
VB
Vanessa Broadhurst
Detailed
Director
WR
Willie Reed
Detailed
Director
Research analysts who have asked questions during Zoetis earnings calls.
CS
Christopher Schott
JPMorgan Chase & Co.
5 questions for ZTS
Also covers: ABBV, AMGN, AMRX +15 more
EW
Erin Wright
Morgan Stanley
5 questions for ZTS
Also covers: ALGN, BTSG, CAH +18 more
BV
Brandon Vazquez
William Blair & Company, L.L.C.
4 questions for ZTS
Also covers: ALGN, CBLL, CVRX +16 more
Jonathan Block
Stifel Financial Corp.
4 questions for ZTS
Also covers: ALGN, COO, CUTR +11 more
Michael Ryskin
Bank of America Merrill Lynch
4 questions for ZTS
Also covers: A, ALGN, AVTR +28 more
NT
Navann Ty
BNP Paribas S.A.
4 questions for ZTS
Also covers: COO, ELAN, EOLS +4 more
CL
Christopher LoBianco
TD Cowen
3 questions for ZTS
Also covers: NVAX
Daniel Clark
Leerink Partners
3 questions for ZTS
Also covers: CERT, ELAN, IDXX +3 more
David Westenberg
Piper Sandler
3 questions for ZTS
Also covers: ADPT, AKYA, BLLN +13 more
AA
Andrea Alfonso
UBS
2 questions for ZTS
Also covers: ELAN
BP
Balaji Prasad
Barclays
2 questions for ZTS
Also covers: ALVO, AMRX, ELAN +7 more
Daniel Christopher Clark
Leerink Partners
2 questions for ZTS
Also covers: DOCS, GDRX, IDXX
GS
Glen Santangelo
Jefferies
2 questions for ZTS
Also covers: ALGN, ANIP, BHC +9 more
JB
Jon Block
Stifel, Nicolaus & Company, Incorporated
2 questions for ZTS
Also covers: COO, DXCM, ELAN +1 more
MR
Michael Riskin
Bank of America
2 questions for ZTS
Also covers: IDXX, LH
NT
Navann Ty Dietschi
BNP Paribas
2 questions for ZTS
Also covers: COO, ELAN, EOLS +6 more
AZ
Andrea Zayco Narvaez Alfonso
UBS
1 question for ZTS
Also covers: ELAN, EVH, LFST
BV
Brandon Vasquez
William Blair & Company
1 question for ZTS
Also covers: HSIC, NVST
Chris
TD Cowen
1 question for ZTS
Also covers: CECO, SITE, UAA
KS
Kris Schott
JPMorgan Chase & Co.
1 question for ZTS
RY
Russell Yuan
William Blair
1 question for ZTS
Sidharth Sahoo
HSBC
1 question for ZTS
Steve Scala
Cowen
1 question for ZTS
Also covers: ABBV, AZN, BMY +6 more
Recent press releases and 8-K filings for ZTS.
Zoetis outlines growth strategies at 44th Annual J.P. Morgan Healthcare Conference
ZTS
Guidance Update
Share Buyback
- Zoetis highlighted the animal health market growing from $50 billion today to $90 billion by 2035, driven by companion-animal medicalization and livestock protein demand; Zoetis has outpaced the industry with 8% CAGR since IPO vs. 5% industry CAGR.
- The company’s “science-to-scale” model includes 1,600 R&D colleagues, $5 billion invested since IPO, and 2,000 regulatory approvals (35% industry share) over the past decade, supporting a pipeline of 12 potential blockbuster drugs with at least one major approval expected annually.
- Commercial execution is powered by a direct field force in 45 markets, omnichannel engagement, and leading franchises—e.g., Simparica Trio (85% owner satisfaction; 60% puppy penetration) and a dermatology suite with Apoquel, Cytopoint, and a long-acting Cytopoint launch planned in 2026.
- Financial discipline has delivered 8–9% revenue growth, 41–42% EBITDA margins, and mid-20s ROIC over five years; Zoetis returned over 125% of free cash flow through dividends and > $3.2 billion in buybacks (last 12 months) while guiding 5.5–6.5% revenue growth in 2025.
Jan 12, 2026, 6:30 PM
Zoetis outlines growth strategy at J.P. Morgan Healthcare Conference
ZTS
Guidance Update
Share Buyback
Debt Issuance
- Zoetis highlighted the essential animal health industry’s expansion from $50 billion today to an expected $90 billion over the next 10 years, driven by companion animal medicalization and livestock protein demand.
- The company’s science-to-scale model has delivered 35% of industry regulatory approvals in the past decade with $5 billion invested in R&D since IPO, and it expects a major market approval every year.
- Key growth drivers include market-leading products in parasiticides (Simparica Trio), dermatology (Apoquel, Cytopoint), and planned launches of long-acting osteoarthritis therapies Solensia and Librela in H1 2026.
- Zoetis achieved 8%–9% revenue CAGR over five years with 41%–42% EBITDA margins and mid-20s ROIC, returning over $3.2 billion in share buybacks in the past 12 months while maintaining an investment-grade balance sheet.
- The company reiterated 2025 revenue growth guidance of 5.5%–6.5%, supported by 2%–3% pricing, franchise expansion in dermatology and parasiticides, robust livestock and diagnostics performance, and disciplined P&L execution.
Jan 12, 2026, 6:30 PM
Zoetis outlines growth strategy and financial performance at J.P. Morgan Healthcare Conference
ZTS
- Animal Health market projected to nearly double to ~$90 billion by 2035, driven by secular tailwinds in both companion animal and livestock segments.
- Zoetis has outpaced the market, delivering an 8% revenue CAGR since its 2013 IPO versus 5% for the Animal Health industry.
- Robust pipeline with expected annual major approvals and 12 potential blockbusters through 2030+ across diverse therapeutic areas.
- Strong financial track record with 8–9% revenue growth, 41–42% adjusted EBITDA margin, and 26–27% ROIC on average over the past five years.
Jan 12, 2026, 6:30 PM
Zoetis outlines growth outlook and strategic priorities at J.P. Morgan Healthcare Conference
ZTS
Guidance Update
Debt Issuance
Share Buyback
- Zoetis forecasts 5.5–6.5% revenue growth in 2025 despite U.S. macro headwinds, leveraging strength in livestock, diagnostics, and core franchises while maintaining disciplined P&L execution for margin expansion.
- The company’s science-to-scale model has driven an 8% CAGR since its IPO—outpacing the industry’s 5% over the same period—and Zoetis led 35% of animal health regulatory approvals in the past decade, backed by $5 billion in R&D investment.
- Management highlighted a robust pipeline of 12 potential blockbuster drugs, expecting at least one major market approval annually—including long-acting Cytopoint this year and future launches in renal, oncology, cardiology, obesity, and anxiety—targeting a $7 billion total addressable market.
- In December, Zoetis completed a convertible debt issuance and $3.2 billion in share buybacks over 12 months, returning over 125% of free cash flow to shareholders while preserving an investment-grade balance sheet.
Jan 12, 2026, 6:30 PM
Zoetis proposes $1.75 billion convertible senior notes offering
ZTS
Debt Issuance
Share Buyback
- Zoetis announced a proposed private offering of $1.75 billion aggregate principal amount of 0.25% convertible senior notes due 2029, with an option for an additional $250 million.
- Net proceeds are intended to fund capped call transactions, purchase shares of Zoetis common stock in privately negotiated transactions, and repurchase additional shares under its existing $6 billion buyback program by Q1 2026.
- The notes will bear interest at 0.25% per annum, payable semi-annually, and will mature on June 15, 2029, with conversion rights subject to specified conditions and settlement in cash, stock, or a combination thereof at Zoetis’s election.
Dec 18, 2025, 9:17 PM
Zoetis prices $1.75 billion convertible senior notes
ZTS
Debt Issuance
Share Buyback
Convertible Preferred Issuance
- Zoetis priced $1.75 billion of 0.25% convertible senior notes due 2029, with an option for an additional $250 million, expected to close December 18, 2025.
- Net proceeds of approximately $1,723.2 million (or $1,969.6 million if the option is exercised) will fund $1.6 billion of common stock repurchases (up to $1.8 billion) and capped call transactions.
- The notes carry a 0.25% coupon, mature June 15, 2029, and are initially convertible at 6.7476 shares per $1,000 principal (≈$148.20 per share).
- Zoetis entered capped call transactions with a cap price of $211.7150 per share (75% premium) to mitigate dilution on conversion.
Dec 16, 2025, 6:15 AM
Zoetis proposes $1.75 billion convertible senior notes offering
ZTS
Debt Issuance
Share Buyback
- Zoetis intends to offer $1.75 billion aggregate principal amount of convertible senior notes due June 15, 2029, with an option for up to an additional $250 million.
- Net proceeds will fund capped call transactions and repurchase common stock under its $6 billion share buyback program, with remaining repurchases expected by Q1 2026.
- The notes will be senior, unsecured, accrue interest semi-annually and, upon conversion, Zoetis may settle obligations in cash, shares, or a combination at its election.
Dec 15, 2025, 12:09 PM
Zoetis declares Q1 2026 dividend
ZTS
Dividends
- On December 11, 2025, Zoetis declared a $0.53 per share dividend for Q1 2026, a 6% increase from the quarterly rate paid in 2025.
- The dividend will be paid on March 3, 2026, to shareholders of record as of January 20, 2026.
Dec 11, 2025, 9:17 PM
Zoetis declares Q1 2026 dividend, approves 6% increase
ZTS
Dividends
- Zoetis’ Board approved a $0.53 per share dividend for Q1 2026, a 6% increase from the quarterly rate paid in 2025.
- The dividend will be paid on March 3, 2026 to holders of record as of January 20, 2026.
- Zoetis generated $9.3 billion in revenue in 2024 and has approximately 13,800 employees, underscoring its leading animal health franchise.
Dec 11, 2025, 9:15 PM
Zoetis presents at Piper Sandler 37th Annual Healthcare Conference
ZTS
Product Launch
Share Buyback
- Zoetis emphasized its science-to-scale R&D engine, leveraging AI, genetics and diagnostics to start development in target species, resulting in faster timelines and lower costs versus human health peers.
- The company plans to launch a blockbuster (> $100 M) product each year through 2029, starting with a long-acting Cytopoint in 2026 (USDA approval), renal CKD therapy in H2 2027, and oncology assets in 2028-29, opening $5 B+ in new markets.
- Chronic kidney disease (CKD) represents a $3 B–$4 B addressable market with no current treatments; Zoetis has seven assets (therapeutics and diagnostics) and expects its first CKD launch in 2027 to enable earlier intervention in dogs and cats.
- Librela in the U.S. shows stabilization with > 75% pet-owner satisfaction; Zoetis targets a return to growth in H2 2026 via veterinarian education, owner engagement and phase IV studies starting this quarter.
- Management highlighted strong core growth drivers (dermatology, parasiticide, pain, livestock), favorable pet-health trends and noted a gap between their conviction and the stock’s current valuation, maintaining disciplined share buybacks alongside business reinvestment.
Dec 4, 2025, 2:30 PM
Quarterly earnings call transcripts for Zoetis.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more